Duloxetine Capsule, Delayed Release
Product Images NDC 60760-462

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-462). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxc (Duloxetine 60760 462 30)

Label for Duloxetine Delayed-Release Capsules 60 mg, quantity 30, NDC 60760-462-30, manufactured by Ajanta Pharma Limited, India, and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. The label includes instructions to use as directed and storage conditions at controlled room temperature 15-30°C (59-86°F).*

FDA Label Image

Figure01 (Duloxetine Fig01)

A line graph showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: Duloxetine and placebo, depicting the relapse rates up to 200 days. The y-axis represents the proportion of patients with relapse, ranging from 0 to 1.0.*

FDA Label Image

Figure2 (Duloxetine Fig02)

A survival curve chart comparing the proportion of patients with relapse over time for Duloxetine versus placebo. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. Two lines distinguish treatment groups: a dashed line for placebo and a solid line for Duloxetine, showing lower relapse rates for Duloxetine throughout the period.*

FDA Label Image

Figure04 (Duloxetine Fig04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo groups. The graph indicates higher patient improvement percentages with Duloxetine treatments compared to placebo across increasing pain improvement thresholds.*

FDA Label Image

Figure07 (Duloxetine Fig07)

Line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain ranging from >0 to 100%. The y-axis shows percentage of patients improved, from 0 to 100%. Duloxetine shows higher patient improvement percentages across most pain improvement levels than placebo.*

FDA Label Image

Figure08 (Duloxetine Fig08)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines plot patient improvement trends, with Duloxetine showing higher percentages across most improvement levels compared to placebo.*

FDA Label Image

Figure09 (Duloxetine Fig09)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from 0 to 100, while the y-axis shows percentage of patients improved from 0 to 100. Duloxetine shows consistently higher patient improvement percentages compared to placebo across the range.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, showing the molecular arrangement including a naphthalene group, a thiophene ring, and an amine hydrochloride side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.